We are live on
!
Find out more
CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.67B
1-Year Est. Return
89%
This Fund
S&P 500
This Quarter
Est. Return
+18.11%
1 Year Est. Return
+89%
3 Year Est. Return
+264.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$514M
AUM Growth
+$169M
(+49%)
Cap. Flow
+$103M
Cap. Flow
% of AUM
19.96%
Top 10 Holdings %
Top 10 Hldgs %
26.88%
Holding
503
New
57
Increased
239
Reduced
90
Closed
78
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$6.25M |
| 2 |
Gilead Sciences
GILD
|
+$6.13M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$6.05M |
| 4 |
Amgen
AMGN
|
+$5.9M |
| 5 |
Adobe
ADBE
|
+$5.02M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.85M |
| 2 |
Analog Devices
ADI
|
+$3.37M |
| 3 |
Amazon
AMZN
|
+$3.21M |
| 4 |
lululemon athletica
LULU
|
+$2.87M |
| 5 |
Oracle
ORCL
|
+$1.91M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 34.39% |
| 2 | Healthcare | 30.05% |
| 3 | Consumer Discretionary | 17.55% |
| 4 | Communication Services | 6.11% |
| 5 | Consumer Staples | 4.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Paychex
PAYX
$42.8B
| $85.9K | 0.02% |
721
-622
| -46% | -$73.7K |
|
302
ALX Oncology
ALXO
$278M
| $85.8K | 0.02% |
5,762
+4,706
| +446% | +$44.6K |
|
303
American Electric Power
AEP
$67.9B
| $85.4K | 0.02% |
1,052
-868
| -45% | -$67.4K |
|
|
GRCL
304
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $84.4K | 0.02% |
8,405
+6,657
| +381% | +$30.2K |
|
305
Zymeworks
ZYME
$1.77B
| $84.2K | 0.02% |
+8,100
| New | +$64.6K |
|
|
SLRN
306
DELISTED
ACELYRIN
SLRN
| $84K | 0.02% |
+11,259
| New | +$96.1K |
|
307
OmniAb
OABI
$497M
| $83K | 0.02% |
+13,450
| New | +$66.1K |
|
308
Adaptive Biotechnologies
ADPT
$4.02B
| $82.1K | 0.02% |
16,747
+13,028
| +350% | +$59.4K |
|
|
FUSN
309
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $80.5K | 0.02% |
+8,376
| New | +$40.7K |
|
310
Edgewise Therapeutics
EWTX
$4.73B
| $80.3K | 0.02% |
7,338
+5,704
| +349% | +$40K |
|
|
DDL
311
Dingdong
DDL
$509M
| $80.3K | 0.02% |
53,514
| – | – |
|
312
Vera Therapeutics
VERA
$2.16B
| $79.1K | 0.02% |
+5,143
| New | +$65.3K |
|
313
Travere Therapeutics
TVTX
$5.86B
| $78.1K | 0.02% |
8,690
+6,773
| +353% | +$49.3K |
|
314
Alector
ALEC
$240M
| $77.7K | 0.02% |
9,733
+7,584
| +353% | +$44.9K |
|
315
Tarsus Pharmaceuticals
TARS
$3.07B
| $77.6K | 0.02% |
3,832
+3,004
| +363% | +$50.2K |
|
|
RNAM
316
DELISTED
Avidity Biosciences
RNAM
| $77.6K | 0.02% |
8,570
+6,675
| +352% | +$44.6K |
|
317
Cognizant
CTSH
$26.2B
| $75.5K | 0.01% |
1,000
-882
| -47% | -$60.9K |
|
318
Constellation Energy
CEG
$98.7B
| $74K | 0.01% |
633
-565
| -47% | -$65.9K |
|
319
Savara
SVRA
$1.17B
| $73.6K | 0.01% |
+15,654
| New | +$60K |
|
|
EA
320
DELISTED
Electronic Arts
EA
| $73.2K | 0.01% |
535
-474
| -47% | -$62.6K |
|
321
Fastenal
FAST
$59.9B
| $73K | 0.01% |
2,254
-2,004
| -47% | -$60.4K |
|
|
BCYC
322
Bicycle Therapeutics
BCYC
$284M
| $72.3K | 0.01% |
4,001
+3,322
| +489% | +$55K |
|
323
Exelon
EXC
$46.6B
| $71.9K | 0.01% |
2,003
-1,705
| -46% | -$65.7K |
|
324
Kiniksa Pharmaceuticals
KNSA
$6.1B
| $71.9K | 0.01% |
4,097
+3,186
| +350% | +$52.4K |
|
325
CoStar Group
CSGP
$12.4B
| $71.3K | 0.01% |
816
-706
| -46% | -$57.1K |
|
Similar funds
HA
JPM
CPO
LCI
GWM
JIP
RMC
GACM
China Universal Asset Management Company's Q4 2023 Portfolio in Review
As of Q4 2023, China Universal Asset Management Company held 503 positions worth $514M, up 49% from $345M the previous quarter. Its ten largest holdings account for 27% of the portfolio.
China Universal Asset Management Company deployed $103M of net new capital in Q4 2023, opening 57 new positions and adding to 239 existing holdings. Its largest new stake was GSK: 54,345 shares worth $2.03M.
By sector, the portfolio is most concentrated in Technology at 34% of assets, down from 38% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was NVIDIA, an estimated $4.85M trimmed.
- China Universal Asset Management Company's largest Q4 2023 buy was GSK: 54,345 shares worth $2.03M.
- China Universal Asset Management Company added most to Vertex Pharmaceuticals in Q4 2023, an estimated $6.25M increase.
- China Universal Asset Management Company's biggest Q4 2023 reduction was NVIDIA, cutting an estimated $4.85M.
- China Universal Asset Management Company fully exited Oracle in Q4 2023, selling an estimated $1.91M.
- China Universal Asset Management Company's ten largest holdings make up 27% of its $514M portfolio in Q4 2023.
- China Universal Asset Management Company opened 57 new positions and closed 78 in Q4 2023.
- China Universal Asset Management Company's portfolio value rose 49% quarter-over-quarter to $514M.
Based on China Universal Asset Management Company's 13F filing for Q4 2023, filed 24 Jan 2024.